23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
In an exciting development, 23andMe has become the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, providing valuable medication insights. One such report focuses on simvastatin, a widely prescribed lipid-lowering statin.
Genetics can significantly influence how our bodies respond to medications, and this is particularly true for statins like simvastatin. Understanding these genetic factors can help healthcare providers tailor treatment plans to individual patients.
On July 20th, 2023, in South San Francisco, 23andMe Holding Co. (Nasdaq: ME), a leading company in human genetics and biopharmaceuticals, announced the release of their new Simvastatin Medication Insight report. This report is part of their exclusive 23andMe+ membership service and provides users with information about their likelihood